Application of a blood-brain-barrier-penetrating form of GDNF in a mouse model for Parkinson's disease

Brain Research

Volumn 1082, Issue 1, 2006, Pages 61-66

  Dietz, Gunnar P H ^a,b   Valbuena, Paola C ^a,b   Dietz, Birgit ^a,b   Meuer, Katrin ^a,b   Müller, Patrick ^a,b   Weishaupt, Jochen H ^a,b   Bähr, Mathias ^a,b  

^a UNIVERSITY MEDICAL CENTER GÖTTINGEN   (Germany)

^b Deutsche Forschungsgemeinschaft   (Germany)

Author keywords

Blood brain barrier; Cell penetrating peptide (CPP); MPTP mouse model; Neuroprotection; Protein transduction domain (PTD)

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; RECOMBINANT PROTEIN; TAT GNDF FUSION PROTEIN; TRANSACTIVATOR PROTEIN; TYROSINE 3 MONOOXYGENASE; UNCLASSIFIED DRUG;

AGED; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD BRAIN BARRIER; CELL SURVIVAL; CONTROLLED STUDY; DOPAMINERGIC NERVE CELL; IMMUNOCOMPETENT CELL; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; MOUSE; NEUROPROTECTION; NIGRONEOSTRIATAL SYSTEM; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; SUBSTANTIA NIGRA; TREATMENT FAILURE;

1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE; ANIMALS; BLOOD-BRAIN BARRIER; CELL COUNT; DISEASE MODELS, ANIMAL; DRUG INTERACTIONS; GENE PRODUCTS, TAT; GENE TRANSFER TECHNIQUES; GENES, TAT; GENETIC VECTORS; GLIAL CELL LINE-DERIVED NEUROTROPHIC FACTOR; IMMUNOHISTOCHEMISTRY; LENTIVIRUS; MICE; NEUROPROTECTIVE AGENTS; PARKINSON DISEASE; PEPTIDES; SUBSTANTIA NIGRA; TYROSINE 3-MONOOXYGENASE;

ANIMALIA; HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 33645841626     PISSN: 00068993     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.brainres.2006.01.083     Document Type: Article

References (37)

1. Albayrak S., Zhao Q., Siesjo B.K., and Smith M.L. Effect of transient focal ischemia on blood-brain barrier permeability in the rat: correlation to cell injury. Acta Neuropathol. (Berl.) 94 (1997) 158-163
2. Belayev L., Busto R., Zhao W., and Ginsberg M.D. Quantitative evaluation of blood-brain barrier permeability following middle cerebral artery occlusion in rats. Brain Res. 739 (1996) 88-96
3. Bjorklund A., Rosenblad C., Winkler C., and Kirik D. Studies on neuroprotective and regenerative effects of GDNF in a partial lesion model of Parkinson's disease. Neurobiol. Dis. 4 (1997) 186-200
4. Damier P., Hirsch E.C., Agid Y., and Graybiel A.M. The substantia nigra of the human brain. II. Patterns of loss of dopamine-containing neurons in Parkinson's disease. Brain 122 (1999) 1437-1448
5. Dawson D.A., Wadsworth G., and Palmer A.M. A comparative assessment of the efficacy and side-effect liability of neuroprotective compounds in experimental stroke. Brain Res. 892 (2001) 344-350
6. Debyser Z. Biosafety of lentiviral vectors. Curr. Gene Ther. 3 (2003) 517-525
7. L delivery protects retinal ganglion cells during experimental autoimmune optic neuritis. Neurobiol. Dis. 20 (2005) 218-226
8. Dietz G.P.H., and Bähr M. Delivery of bioactive molecules into the cell: the Trojan horse approach. Mol. Cell. Neurosci. 27 (2004) 85-131
9. Dietz G.P.H., and Bähr M. Peptide-enhanced cellular internalization of proteins in neuroscience. Brain Res. Bull. 68 1-2 (2005) 103-114
10. Dietz G.P.H., Kilic E., and Bähr M. Inhibition of neuronal apoptosis in vitro and in vivo using TAT-mediated protein transduction. Mol. Cell. Neurosci. 21 (2002) 29-37
11. Eberhardt O., Coelln R.V., Kügler S., Lindenau J., Rathke-Hartlieb S., Gerhardt E., Haid S., Isenmann S., Gravel C., Srinivasan A., Bähr M., Weller M., Dichgans J., and Schulz J.B. Protection by synergistic effects of adenovirus-mediated X-chromosome-linked inhibitor of apoptosis and glial cell line-derived neurotrophic factor gene transfer in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of Parkinson's disease. J. Neurosci. 20 (2000) 9126-9134
12. Ebert S., Dietz G.P.H., Mitchell T.J., Michel U., Bähr M., and Nau R. Limited protection of TAT-Bcl-X(L) against pneumolysin-induced neuronal cell death. Neurosci. Lett. 384 (2005) 349-353
13. Gash D.M., Zhang Z., Ovadia A., Cass W.A., Yi A., Simmerman L., Russell D., Martin D., Lapchak P.A., Collins F., Hoffer B.J., and Gerhardt G.A. Functional recovery in parkinsonian monkeys treated with GDNF. Nature 380 (1996) 252-255
14. Gill S.S., Patel N.K., Hotton G.R., O'Sullivan K., McCarter R., Bunnage M., Brooks D.J., Svendsen C.N., and Heywood P. Direct brain infusion of glial cell line-derived neurotrophic factor in Parkinson disease. Nat. Med. 9 (2003) 589-595
15. Grondin R., Zhang Z., Yi A., Cass W.A., Maswood N., Andersen A.H., Elsberry D.D., Klein M.C., Gerhardt G.A., and Gash D.M. Chronic, controlled GDNF infusion promotes structural and functional recovery in advanced parkinsonian monkeys. Brain 125 (2002) 2191-2201
16. Heikkila R.E., Hess A., and Duvoisin R.C. Dopaminergic neurotoxicity of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine in mice. Science 224 (1984) 1451-1453
17. Irwin I., DeLanney L.E., and Langston J.W. MPTP and aging. Studies in the C57BL/6 mouse. Adv. Neurol. 60 (1993) 197-206
18. Kilic E., Dietz G.P.H., Hermann D.M., and Bähr M. Intravenous TAT-Bcl-XL is protective after middle cerebral artery occlusion in mice. Ann. Neurol. 52 (2002) 617-622
19. Kilic U., Kilic E., Dietz G.P.H., and Bähr M. Intravenous TAT-GDNF is protective after focal cerebral ischemia in mice. Stroke 34 (2003) 1304-1310
20. Kilic U., Kilic E., Dietz G.P.H., and Bähr M. The TAT protein transduction domain enhances the neuroprotective effect of GDNF after optic nerve transection. Neurodegener. Dis. 1 (2004) 44-49
21. Koller W.C., and Cersosimo M.G. Neuroprotection in Parkinson's disease: an elusive goal. Curr. Neurol. Neurosci. Rep. 4 (2004) 277-283
22. Kordower J.H., Palfi S., Chen E.Y., Ma S.Y., Sendera T., Cochran E.J., Mufson E.J., Penn R., Goetz C.G., and Comella C.D. Clinicopathological findings following intraventricular glial-derived neurotrophic factor treatment in a patient with Parkinson's disease. Ann. Neurol. 46 (1999) 419-424
23. Kordower J.H., Emborg M.E., Bloch J., Ma S.Y., Chu Y., Leventhal L., McBride J., Chen E.Y., Palfi S., Roitberg B.Z., Brown W.D., Holden J.E., Pyzalski R., Taylor M.D., Carvey P., Ling Z., Trono D., Hantraye P., Deglon N., and Aebischer P. Neurodegeneration prevented by lentiviral vector delivery of GDNF in primate models of Parkinson's disease. Science 290 (2000) 767-773
24. Langston J.W., Langston E.B., and Irwin I. MPTP-induced parkinsonism in human and non-human primates-Clinical and experimental aspects. Acta Neurol. Scand., Suppl. 100 (1984) 49-54
25. Lin L.F., Doherty D.H., Lile J.D., Bektesh S., and Collins F. GDNF: a glial cell line-derived neurotrophic factor for midbrain dopaminergic neurons. Science 260 (1993) 1130-1132
26. Menzies S.A., Betz A.L., and Hoff J.T. Contributions of ions and albumin to the formation and resolution of ischemic brain edema. J. Neurosurg. 78 (1993) 257-266
27. Nagahara H., Vocero-Akbani A.M., Snyder E.L., Ho A., Latham D.G., Lissy N.A., Becker-Hapak M., Ezhevsky S.A., and Dowdy S.F. Transduction of full-length TAT fusion proteins into mammalian cells: TAT-p27Kip1 induces cell migration. Nat. Med. 4 (1998) 1449-1452
28. Nutt J.G., Burchiel K.J., Comella C.L., Jankovic J., Lang A.E., Laws Jr. E.R., Lozano A.M., Penn R.D., Simpson Jr. R.K., Stacy M., and Wooten G.F. Randomized, double-blind trial of glial cell line-derived neurotrophic factor (GDNF) in PD. Neurology 60 (2003) 69-73
29. Palfi S., Leventhal L., Chu Y., Ma S.Y., Emborg M., Bakay R., Deglon N., Hantraye P., Aebischer P., and Kordower J.H. Lentivirally delivered glial cell line-derived neurotrophic factor increases the number of striatal dopaminergic neurons in primate models of nigrostriatal degeneration. J. Neurosci. 22 (2002) 4942-4954
30. Pardridge W.M. CNS drug design based on principles of blood-brain barrier transport. J. Neurochem. 70 (1998) 1781-1792
31. Pardridge W.M. Neurotrophins, neuroprotection and the blood-brain barrier. Curr. Opin. Investig. Drugs 3 (2002) 1753-1757
32. Patel N.K., Bunnage M., Plaha P., Svendsen C.N., Heywood P., and Gill S.S. Intraputamenal infusion of glial cell line-derived neurotrophic factor in PD: a two-year outcome study. Ann. Neurol. 57 (2005) 298-302
33. Przedborski S., Tieu K., Perier C., and Vila M. MPTP as a mitochondrial neurotoxic model of Parkinson's disease. J. Bioenerg. Biomembr. 36 (2004) 375-379
34. Schwarze S.R., Ho A., Vocero-Akbani A., and Dowdy S.F. In vivo protein transduction: delivery of a biologically active protein into the mouse. Science 285 (1999) 1569-1572
35. Slevin J.T., Gerhardt G.A., Smith C.D., Gash D.M., Kryscio R., and Young B. Improvement of bilateral motor functions in patients with Parkinson disease through the unilateral intraputaminal infusion of glial cell line-derived neurotrophic factor. J. Neurosurg. 102 (2005) 216-222
36. Tomac A., Lindqvist E., Lin L.F., Ogren S.O., Young D., Hoffer B.J., and Olson L. Protection and repair of the nigrostriatal dopaminergic system by GDNF in vivo. Nature 373 (1995) 335-339
37. Weiss R. Promising protein for Parkinson's. Science 260 (1993) 1072-1073